Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in PALB2-related Advanced Pancreatic Cancer
NCT06078787Phase 2Recruiting
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in pancreatic adenocarcinoma (PDAC), sponsored by Azienda Ospedaliera Universitaria Policlinico. Started Aug 2023; status: recruiting.
02
Drugs
olaparib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06078787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078787.